Over the last year and a half, the pandemic has quickly accelerated the scientific world. Since the COVID-19 outbreak started, experts around the globe have switched their focus to battling the virus. While the novel coronavirus came out of the blue, this new wealth of research could go a long way toward protecting us from similar threats in the future.
At the forefront of the fight against the COVID-19 outbreak is a new approach. Scientists have been working hard to decode the genome that caused the virus. The aim is to gain an in-depth understanding of how the microbe works and utilize that information when battling the virus. The truth of the matter is that the virus is constantly mutating. For that reason, it’s never been more important for researchers to identify new variations as they appear and keep an accurate track of these virus changes.
Experts around the world add this information to the Global Initiative on Sharing All Influenza Data (GISAID), a public database that can be accessed by other researchers. Thanks to this collaboration, governing bodies can make an informed decision when making public health decisions. The live and up-to-date information allows the world’s most influential policy-makers to move forward.
Centers for Disease Control and Prevention (CDC) Funding
Back in April, Congress set aside $1.7 billion for the Centers for Disease Control and Prevention (CDC) to support its genome sequencing activities. The funding should help ensure consistent genetic sweeps of samples across the country while making way for collaborations, such as the one with MAKO Medical Laboratories. Through these partnerships, the United States’ leading laboratories can work to create a stable and functional genetic-based system of disease reconnaissance. Experts will be able to use the system in the future to identify new pathogens and keep track of any new microbes that could threaten public health.
The CDC has teamed up with a wealth of partners across the country, allowing them to sequence between 20,000 and 30,000 SARS-CoV-2 genomes every week. It’s a gigantic leap in the right direction. However, it’s worth noting that states are currently sequencing less than two percent of the positive samples they gain.
MAKO Medical Laboratories Partnership
MAKO Medical Laboratories, a leading testing and research lab company, has played a key role in this mission. Since the pandemic began, CEO Chad Price made the move to start COVID-19 testing and research in both of the healthcare brand’s laboratories. With an expert team of doctors and PhDs working hard to recognize new mutations of the virus, the team has been successful in offering up-to-date information on the novel coronavirus.
Since the start of this year, the researchers at MAKO Medical Laboratories have used sequencing processes to analyze more than 2,5000 samples from tests in 43 states. The move has led the laboratories’ experts to identify a number of new variations of the SARS-CoV-2 virus. These include the B.1.1.7, B.1.351, and B.1.429 variants. Moreover, the team is continually searching for new mutations as they appear in test results.
“Over the past several months, our sequencing team has identified the emergence of strains like the United Kingdom B.1.1.7, South African, and Denmark variants in states across the country,” said Steve Hoover, Vice President of Laboratory Operations, MAKO Medical. “As new strains are defined, MAKO continues to sequence samples and provide much-needed data to public health professionals.”
Last month, the national reference laboratory formed a partnership with the Centers for Disease Control and Prevention (CDC). This collaboration could have a serious impact on the future of virus prevention and protection. MAKO Medical Laboratories have committed to continually providing the CDC with information based on its next-generation sequencing of SARS-CoV-2.
“The MAKO team is proud to partner with the Centers for Disease Control to provide sequencing services for samples from across the country,” said Josh Arant, Chief Operating Officer, MAKO Medical. “For the past year, our team has been committed to providing rapid, reliable results to patients and providers across forty-three states. We recognized the need to introduce sequencing for a portion of samples our team collected earlier this year and are honored to apply that experience in this partnership.”
About MAKO Medical Laboratories
Supported by an expert team of nationally recognized doctors and PhDs, MAKO Medical Laboratories specializes in methodology development and pathological services. The game-changing testing company and labs prioritize patients by offering transparency.
Started in 2014 by Chad Price, Adam Price, and Josh Arant, it aims to disrupt the sector. Additionally, MAKO Medical offers support to veterans. The company combines a wealth of new technology including robotics, app platforms, and cloud-based tech. In response to the pandemic, the laboratories have adapted their services to offer accurate testing.
Chad Price is the CEO of MAKO Medical Laboratories. He has had a long entrepreneurial career previously co-founding BrideGenie and founding Element Services Group Mechanical LLC. He has played a major role in starting Cary Reconstruction and is a board member for Trill A.I. Moreover, he currently offers tailored consulting services to companies embarking on new mergers or primed for growth